THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA BY CONTINUOUS INTRAVENOUS-INFUSION OF RECOMBINANT INTERLEUKIN-2

被引：24

作者：

GORE, ME

GALLIGIONI, E

KEEN, CW

SORIO, R

LORIAUX, EM

GROBBEN, HC

FRANKS, CR

机构：

[1] CTR RIFERIMENTO ONCOL,AVIANO,ITALY

[2] MAIDSTONE HLTH AUTHOR,MAIDSTONE,KENT,ENGLAND

[3] EUROCETUS BV,AMSTERDAM,NETHERLANDS

来源：

EUROPEAN JOURNAL OF CANCER | 1994年 / 30A卷 / 03期

关键词：

INTERLEUKIN-2; RENAL CELL CARCINOMA;

D O I：

10.1016/0959-8049(94)90251-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Between March 1989 and June 1990, 133 patients were treated with interleukin 2 (rIL-2) for metastatic renal cell carcinoma (RCC) in a multicentre open non-randomised study. The results show an objective response rate of 14% (95% confidence interval 8-21) with 4 patients achieving a complete remission. This is in keeping with the data from previous studies using rIL-2 by continuous infusion. It is of interest that 87% of objective responses occurred in hospitals that entered 5 or more patients.

引用

页码：329 / 333

页数：5

共 15 条

[1] PHASE-II TRIAL OF HIGH-DOSE INTERMITTENT INTERLEUKIN-2 IN METASTATIC RENAL-CELL CARCINOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY
BUKOWSKI, RM
GOODMAN, P
CRAWFORD, ED
SERGI, JS
REDMAN, BG
WHITEHEAD, RP
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (02) : 143 - 146
[2] TREATMENT OF ADVANCED RENAL-CELL CARCINOMA - TRADITIONAL METHODS AND INNOVATIVE APPROACHES
DEKERNION, JB
[J]. JOURNAL OF UROLOGY, 1983, 130 (01) : 2 - 7
[3] NATURAL-HISTORY OF METASTATIC RENAL CELL-CARCINOMA - COMPUTER-ANALYSIS
DEKERNION, JB
RAMMING, KP
SMITH, RB
[J]. JOURNAL OF UROLOGY, 1978, 120 (02) : 148 - 152
[4] ELSON PJ, 1988, CANCER RES, V48, P7310
[5] HARRIS DT, 1983, SEMIN ONCOL, V10, P422
[6] AN ASSESSMENT OF THE CURRENT USE OF HUMAN INTERFERONS IN THERAPY OF UROLOGICAL CANCERS
HOROSZEWICZ, JS
MURPHY, GP
[J]. JOURNAL OF UROLOGY, 1989, 142 (05) : 1173 - 1180
[7] NEGRIER S, 1989, EUR J CANCER CLIN ON, V25, pS21
[8] CONTINUOUS INFUSION OF RECOMBINANT INTERLEUKIN-2 WITH OR WITHOUT AUTOLOGOUS LYMPHOKINE ACTIVATED KILLER-CELLS FOR THE TREATMENT OF ADVANCED RENAL-CELL CARCINOMA
PALMER, PA
VINKE, J
EVERS, P
POURREAU, C
OSKAM, R
ROEST, G
VLEMS, F
BECKER, L
LORIAUX, E
FRANKS, CR
[J]. EUROPEAN JOURNAL OF CANCER, 1992, 28A (6-7) : 1038 - 1044
[9] PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA TREATED WITH RECOMBINANT INTERLEUKIN-2
PALMER, PA
VINKE, J
PHILIP, T
NEGRIER, S
ATZOPODIEN, J
KIRCHNER, H
OSKAM, R
FRANKS, CR
[J]. ANNALS OF ONCOLOGY, 1992, 3 (06) : 475 - 480
[10] THERAPY OF RENAL-CELL CARCINOMA WITH INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER-CELLS - PHASE-II EXPERIENCE WITH A HYBRID BOLUS AND CONTINUOUS INFUSION INTERLEUKIN-2 REGIMEN
PARKINSON, DR
FISHER, RI
RAYNER, AA
PAIETTA, E
MARGOLIN, KA
WEISS, GR
MIER, JW
SZNOL, M
GAYNOR, ER
BAR, MH
GUCALP, R
BOLDT, DH
MILLS, B
HAWKINS, MJ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (10) : 1630 - 1636

← 1 2 →